Volume 2 Supplement 1

ESICM LIVES 2014

Open Access

0737. Statins protect the vasculature from excessive angpt-2 production in sepsis

  • K Thamm1,
  • C Ghosh2,
  • JT Kielstein1,
  • WC Aird2,
  • A Santel3,
  • SM Parikh2 and
  • S David1
Intensive Care Medicine Experimental20142(Suppl 1):P59

DOI: 10.1186/2197-425X-2-S1-P59

Published: 26 September 2014

Introduction

Sepsis is a syndrome of systemic inflammation arising from infection that constitutes a top-ten cause of adult mortality. The recent withdrawal of a specific sepsis therapeutic has diminished pharmaceutical enthusiasm for developing novel drugs in this domain. Angiopoietin-2 (Angpt-2) is an endothelial-derived protein that potentiates vascular inflammation and permeability and may be involved in sepsis pathogenesis.

Objectives

We set out to screen well-established drugs for their Angpt-2 lowering potential to ameliorate sepsis morbidity and to analyse the underlying molecular mechanism.

Methods

In vitro

FDA-approved library screening in human umbilical vein endothelial cells (HUVECs) and confirmation via Angpt-2 ELISA and quantitative RT-PCR.

In vivo

Murine experimental sepsis was induced both by endotoxin (LPS) and cecal ligation and puncture (CLP). Mice were either treated with an Angpt-2 specific siRNA, simvastatin, or both and survival as well as the direct effect on Angpt-2 production was assessed by RT-PCR. In men: We analyzed circulating Angpt-2 levels in a retrospective matched case-control study in individuals with septic shock.

Results

We found that simvastatin reduced endothelial Angpt-2 release and transcription in a time- and dose dependent manner in HUVECs. This effect required Simvastatin's HMG-CoA reductase activity. Similarly, in vivo simvastatin reduced the transcription of Angpt-2 murine lungs. In septic mice, specific inhibition of Angpt-2 in the pulmonary endothelium via an RNAi approach improved survival by 50% (p=0.002). Simvastatin equally improved survival, but the combination of Angpt-2 siRNA and simvastatin showed no additive benefit indicating that simvastatin might act via Angpt-2 inhibition. To investigate a potential link between statins and Angpt-2 in humans, we performed a matched case-control study in critically ill subjects and found that prior statin use was associated with lower circulating Angpt-2.

Conclusions

In an unbiased approach Simvastatin was found to inhibit Angpt-2 production in vitro. This observation could be confirmed in vivo in different murine models of the disease. Our data indicate that a potential beneficial effect of prior statin use in septic humans might be promoted via the Angpt-2/Tie2 axis. Therefore, “point of care” screening for circulating Angpt-2 in candidates for a clinical sepsis trial might help to identify those individuals that benefit from a statin treatment.

Declarations

Grant acknowledgment

SD is supported by the DFG (DA 1209/4-1).

Authors’ Affiliations

(1)
Hannover Medical School
(2)
Harvard Medical School, Center for Vascular Biology Research
(3)
Silence Therapeutics AG

Copyright

© Thamm et al; licensee Springer. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement